Physician profile
Ronald G Thomas
NPI 1780746545
$2,344.05
in general payments reported to CMS, 2019-2025
22 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.76 · 2020: $19.28 · 2021: $180 · 2022: $578 · 2023: $402 · 2024: $667 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $690.17 | 2021-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $206.02 | 2022-2025 | |
| Amgen INC. | $181.42 | 2024-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $174.96 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $171.47 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $128.75 | 2019-2024 | Farxiga, Airsupra |
| Abbott Laboratories | $128.13 | 2022 | |
| Glaxosmithkline, LLC. | $107.82 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $91.66 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $76.11 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $53.33 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Pfizer INC. | $52.95 | 2024-2025 | |
| Daiichi Sankyo INC. | $50.32 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $45.59 | 2022-2023 | Quviviq |
| Corcept Therapeutics | $40.86 | 2023-2024 | Korlym |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $36.16 | 2024 | |
| Astellas Pharma US INC | $20.90 | 2024 | Veozah |
| Janssen Pharmaceuticals, INC | $20.83 | 2024 | Spravato |
| Medtronic, INC. | $19.07 | 2024 | Intellis Adaptivestim |
| Sumitomo Pharma America, INC. | $17.71 | 2025 | Gemtesa |
| Noven Therapeutics, LLC | $16.89 | 2024 | Xelstrym |
| Horizon Therapeutics Plc | $12.93 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.